A once-promising vaccine for AIDS may have inadvertently increased the infection risk of people participating in clinical trials, researchers said on Wednesday.
The multinational trials involving more than 3,000 HIV-negative volunteers were canceled last month after a large-scale study found it was not effective at preventing infection.
Further analysis showed that those who received the vaccine had a higher rate of infection than those who received a placebo, said US pharmaceutical giant Merck, which helped develop the vaccine.
The study volunteers who received the vaccine are being advised of their potentially increased susceptibility, Merck said.
"We are analyzing the data to try to determine if the results are due to immune responses induced by the vaccine, differences in study populations, or some other biological phenomenon we don't yet understand, or simply due to chance," said Keith Gottesdiener, vice president of Merck's vaccine and infectious disease clinical research.
"It will take some time before we understand why the vaccine did not work and why there was a trend toward more cases of infection in volunteers who received the vaccine," he said in a statement.
The experimental vaccine cannot cause infection, Merck said.
It was a modified cold virus used to deliver three synthetically produced HIV genes in the hopes of stimulating a response from the immune system.
Unlike earlier failed vaccines which tried to get the immune system to produce antibodies, the V520 vaccine stimulated T cells, the main disease fighters of the body.
These are the cells that HIV infects and uses to replicate itself, leading to a drop in the number of T cells available to fight off other infections.
It's possible that the volunteers became more vulnerable to HIV infection because the vaccine stimulates an increase in the production of T cells, a spokeswoman said.
The randomized, double-blind trials were conducted in various sites in the US, Canada, Peru, Brazil, Dominican Republic, Haiti, Puerto Rico, Jamaica, Australia and South Africa beginning in 2004.
Volunteers, who were already at high-risk of contracting AIDS, were given prevention counseling in addition to the vaccine or placebo. But dozens became infected anyway.
All but one of the infections among those given the vaccine were in male volunteers and the bulk of those infected were homosexual men.
Those with a higher level of pre-existing immunity to the modified cold virus used to deliver the vaccine were twice as likely to have been infected if they received the vaccine.
The initial analysis found 21 cases of HIV infection among the 392 men who received the vaccine while only nine cases were reported among the 386 men with a high level of pre-existing immunity who were given a placebo.
The results are "both disappointing and puzzling," said Anthony Fauci, the director of the US National Institute of Allergy and Infectious Diseases, which co-sponsored the trials.
"Certainly, the failure of this HIV vaccine product was unexpected," he said in a statement.
"But this setback should not and can not diminish our commitment to developing an effective HIV vaccine."
About 12,000 people become infected with HIV every day and vaccines have historically been the most effective tool against infections diseases like polio and smallpox.
While scientists work on developing a vaccine, politicians need to implement proven prevention methods, Fauci said.
Chinese President Xi Jinping (習近平) is to visit Russia next month for a summit of the BRICS bloc of developing economies, Chinese Minister of Foreign Affairs Wang Yi (王毅) said on Thursday, a move that comes as Moscow and Beijing seek to counter the West’s global influence. Xi’s visit to Russia would be his second since the Kremlin sent troops into Ukraine in February 2022. China claims to take a neutral position in the conflict, but it has backed the Kremlin’s contentions that Russia’s action was provoked by the West, and it continues to supply key components needed by Moscow for
Japan scrambled fighter jets after Russian aircraft flew around the archipelago for the first time in five years, Tokyo said yesterday. From Thursday morning to afternoon, the Russian Tu-142 aircraft flew from the sea between Japan and South Korea toward the southern Okinawa region, the Japanese Ministry of Defense said in a statement. They then traveled north over the Pacific Ocean and finished their journey off the northern island of Hokkaido, it added. The planes did not enter Japanese airspace, but flew over an area subject to a territorial dispute between Japan and Russia, a ministry official said. “In response, we mobilized Air Self-Defense
CRITICISM: ‘One has to choose the lesser of two evils,’ Pope Francis said, as he criticized Trump’s anti-immigrant policies and Harris’ pro-choice position Pope Francis on Friday accused both former US president Donald Trump and US Vice President Kamala Harris of being “against life” as he returned to Rome from a 12-day tour of the Asia-Pacific region. The 87-year-old pontiff’s comments on the US presidential hopefuls came as he defied health concerns to connect with believers from the jungle of Papua New Guinea to the skyscrapers of Singapore. It was Francis’ longest trip in duration and distance since becoming head of the world’s nearly 1.4 billion Roman Catholics more than 11 years ago. Despite the marathon visit, he held a long and spirited
The pitch is a classic: A young celebrity with no climbing experience spends a year in hard training and scales Mount Everest, succeeding against some — if not all — odds. French YouTuber Ines Benazzouz, known as Inoxtag, brought the story to life with a two-hour-plus documentary about his year preparing for the ultimate challenge. The film, titled Kaizen, proved a smash hit on its release last weekend. Young fans queued around the block to get into a preview screening in Paris, with Inoxtag’s management on Monday saying the film had smashed the box office record for a special cinema